Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers

Fong, Peter C., Boss, David S., Yap, Timothy A., Tutt, Andrew, Wu, Peijun, Mergui-Roelvink, Marja, Mortimer, Peter, Swaisland, Helen, Lau, Alan, O'Connor, Mark J., Ashworth, Alan, Carmichael, James, Kaye, Stan B., Schellens, Jan H.M., de Bono, Johann S.·2009·New England Journal of Medicine
DOI 10.1056/nejmoa0900212

Cited by (1,012)

Items 501–600 of 1,012

  1. Expanding the Criteria for BRCA Mutation Testing in Breast Cancer Survivors
    Janice S. Kwon, Angelica M. Gutierrez‐Barrera, Diana Young, Charlotte C. Sun, Molly S. Daniels, Karen H. Lu, Banu Arun · 2010 · Journal of Clinical Oncology
  2. Metastatic Triple-negative Breast Cancer
    Emad A. Rakha, Stephen Y.T. Chan · 2011 · Clinical Oncology
  3. Complex DNA repair pathways as possible therapeutic targets to overcome temozolomide resistance in glioblastoma
    Yoshimoto, Koji, Mizoguchi, Masahiro, Hata, Nobuhiro, Murata, Hideki, Hatae, Ryusuke, Amano, Toshiyuki, Nakamizo, Akira, Sasaki, Tomio · 2012 · Frontiers in Oncology
  4. BRCA1 gene: function and deficiency
    Miho Takaoka, Yoshio Miki · 2017 · International Journal of Clinical Oncology
  5. Latest clinical evidence and further development of PARP inhibitors in ovarian cancer
    Mansoor Raza Mirza, Sandro Pignata, Jonathan Andrew Ledermann · 2018 · Annals of Oncology
  6. The kinase polypharmacology landscape of clinical PARP inhibitors
    Albert A. Antolín, Malaka Ameratunga, Udai Banerji, Paul Andrew Clarke, Paul Workman, Bissan Al‐Lazikani · 2020 · Scientific Reports
  7. Selective resistance to the PARP inhibitor olaparib in a mouse model for BRCA1-deficient metaplastic breast cancer
    Linda Henneman, Martine H. van Miltenburg, Ewa Malgorzata Michalak, Tanya M. Braumuller, Janneke E. Jaspers, Anne Paulien Drenth, Renske de Korte‐Grimmerink, Ewa Gogola, Károly Szuhai, Andreas Schlicker et al. · 2015 · Proceedings of the National Academy of Sciences
  8. Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?
    Fanny Le Du, Bedrich L. Eckhardt, Bora Lim, Jennifer Keating Litton, Stacy L. Moulder, Funda Meric‐Bernstam, Ana Maria Gonzalez-Angulo, Naoto Tada Ueno · 2015 · Oncotarget
  9. Augmentation of Response to Chemotherapy by microRNA-506 Through Regulation of RAD51 in Serous Ovarian Cancers
    Guoyan Liu, Da Yang, Rajesha Rupaimoole, Chad Victor Pecot, Yan Sun, Lingegowda Selanere Mangala, Xia Li, Ping Ji, David E. Cogdell, Limei Hu et al. · 2015 · JNCI Journal of the National Cancer Institute
  10. BRCA1/2 mutations and expression: Response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer
    Rebecca Byler Dann, Julie A. DeLoia, Kirsten M. Timms, Kristin K. Zorn, Jennifer Potter, Darl D. Flake, Jerry S. S. Lanchbury, Thomas C. Krivak · 2012 · Gynecologic Oncology
  11. Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer
    Martin David Forster, Konstantin Johannes Dedes, Shahneen Kaur Sandhu, Sophia Frentzas, Rebecca Sophie Kristeleit, Alan Ashworth, Christopher John Poole, Britta Weigelt, Stan B. Kaye, Lulama Rhoda Molife · 2011 · Nature Reviews Clinical Oncology
  12. Role of PARP Inhibitors in Cancer Biology and Therapy
    Diwakar Davar, Jan Hendrik Beumer, Lana Hamieh, Hussein Abdul-Hassan Tawbi · 2012 · Current Medicinal Chemistry
  13. Characteristics of Triple-Negative Breast Cancer in Patients With a BRCA1 Mutation: Results From a Population-Based Study of Young Women
    Eunjung Lee, Roberta McKean‐Cowdin, Huiyan Ma, DARCY V. SPICER, David Van Den Berg, Leslie Bernstein, Giske Ursin · 2011 · Journal of Clinical Oncology
  14. Low ATM protein expression and depletion of p53 correlates with olaparib sensitivity in gastric cancer cell lines
    Eiji Kubota, Christopher T Williamson, Ruiqiong Ye, Anifat A. Elegbede, Lars Peterson, Susan P. Lees‐Miller, Dafydd Gwyn Bebb · 2014 · Cell Cycle
  15. Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours
    Emma Jane Dean, Mark Ross Middleton, Thinn P. Pwint, Helen Swaisland, J Carmichael, P. Goodege, Malcolm Ranson · 2012 · British Journal of Cancer
  16. The USP1/UAF1 Complex Promotes Double-Strand Break Repair through Homologous Recombination
    Junko Murai, Kailin Yang, Donniphat Dejsuphong, Kouji Hirota, Shunichi Takeda, Alan D. D’Andrea · 2011 · Molecular and Cellular Biology
  17. Chemotherapy for Endometrial Cancer in Adjuvant and Advanced Disease Settings
    Christine M. Bestvina, Gini F. Fleming · 2016 · The Oncologist
  18. PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy
    X Bian, Jing Gao, F Luo, Ceng Rui, T Zheng, Dong‐Yu Wang, Y Wang, Thomas M. Roberts, Pengcong Liu, Jean J. Zhao et al. · 2017 · Oncogene
  19. A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours
    Omar Khan, Martin Eric Gore, Paul C. Lorigan, J Stone, Alastair Greystoke, Wendy Burke, J Carmichael, Amanda J. Watson, Gail McGown, Mary R. Thorncroft et al. · 2011 · British Journal of Cancer
  20. Poly(ADP-ribose) polymerase inhibitors in cancer treatment: A clinical perspective
    Shahneen Kaur Sandhu, Timothy Anthony Yap, Johann Sebastian De Bono · 2009 · European Journal of Cancer
  21. Functional Assays for Analysis of Variants of Uncertain Significance inBRCA2
    Lucia Guidugli, Aura Carreira, Sandrine M. Caputo, Åsa Ehlén, Alvaro Galli, Álvaro N.A. Monteiro, Susan L. Neuhausen, Thomas van Overeem Hansen, Fergus J. Couch, Maaike P.G. Vreeswijk · 2013 · Human Mutation
  22. BRCA1 promoter methylation in peripheral blood cells is associated with increased risk of breast cancer with BRCA1 promoter methylation
    Takashi Iwamoto, Noriaki Yamamoto, Tetsuya Taguchi, Yasuhiro Tamaki, Shinzaburo Noguchi · 2010 · Breast Cancer Research and Treatment
  23. DNA double-strand break repair pathways, chromosomal rearrangements and cancer
    Torben Kasparek, Timothy C. Humphrey · 2011 · Seminars in Cell and Developmental Biology
  24. Breast cancer subtypes: response to radiotherapy and potential radiosensitisation
    Fiona E. Langlands, Kieran J. Horgan, David Dodwell, L Smith · 2013 · British Journal of Radiology
  25. Maternal Embryonic Leucine Zipper Kinase (MELK) as a Novel Mediator and Biomarker of Radioresistance in Human Breast Cancer
    Corey Wayne Speers, Shuang George Zhao, Vishal Kothari, Alyssa Santola, Meilan Liu, Kari Wilder-Romans, Joseph R. Evans, Nidhi Batra, Harry G M M Bartelink, Daniel F. Hayes et al. · 2016 · Clinical Cancer Research
  26. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib
    Chen Wang, Nicholas Jette, Daniel Moussienko, Dafydd Gwyn Bebb, Susan P. Lees‐Miller · 2017 · Translational Oncology
  27. Clinical Outcome of Prostate Cancer Patients with Germline DNA Repair Mutations: Retrospective Analysis from an International Study
    Joaquı́n Mateo, Heather H. Cheng, Himisha Beltran, David I. Dolling, Wen Xu, Colin C. Pritchard, Helen Mossop, Pasquale Rescigno, Raquel Pérez-López, Verena Sailer et al. · 2018 · European Urology
  28. Genetic Predisposition to Breast and Ovarian Cancers: How Many and Which Genes to Test?
    Davide Angeli, Samanta Salvi, Gianluca Tedaldi · 2020 · International Journal of Molecular Sciences
  29. Targeting triple negative breast cancer: Is p53 the answer?
    Natalie Heather Turner, Erica Moretti, Olimpia Siclari, Ilenia Migliaccio, Libero Santarpia, Maurizio D’Incalci, Stefano Piccolo, Andrea Veronesi, Alberto Zambelli, Giannino Del Sal et al. · 2013 · Cancer Treatment Reviews
  30. Evidence for a role of the histone deacetylase SIRT6 in DNA damage response of multiple myeloma cells
    Michele Cea, Antonia Cagnetta, Sophia Adamia, Chirag Acharya, Yu‐Tzu Tai, Mariateresa Fulciniti, Hiroto Ohguchi, Aditya Munshi, Prakrati C. Acharya, Manoj Bhasin et al. · 2015 · Blood
  31. Sensitivity to Poly(ADP-ribose) Polymerase (PARP) Inhibition Identifies Ubiquitin-specific Peptidase 11 (USP11) as a Regulator of DNA Double-strand Break Repair
    Timothy D. Wiltshire, Courtney A. Lovejoy, Tong Wang, Fen Xia, Mark J. O’Connor, David Cortez · 2010 · Journal of Biological Chemistry
  32. Genomic Complexity Profiling Reveals That HORMAD1 Overexpression Contributes to Homologous Recombination Deficiency in Triple-Negative Breast Cancers
    Johnathan A. Watkins, Daniel B. Weekes, Vandna Shah, Patrycja Gazińska, Shalaka Prakash Joshi, Bhavna Sidhu, Cheryl Gillett, Sarah E. Pinder, Fabio Vanoli, Maria Jasin et al. · 2015 · Cancer Discovery
  33. Update on PARP Inhibitors in Breast Cancer
    Alexandra S. Zimmer, Mitchell Gillard, Stanley Lipkowitz, Jung‐Min Lee · 2018 · Current Treatment Options in Oncology
  34. “Contextual” Synthetic Lethality and/or Loss of Heterozygosity: Tumor Hypoxia and Modification of DNA Repair
    Norman Hok Ling Chan, Robert Glen Bristow · 2010 · Clinical Cancer Research
  35. Genomic Medicine Frontier in Human Solid Tumors: Prospects and Challenges
    Rodrigo Dienstmann, Jordi Ahnert Rodon, Jordi Barretina, Josep M. Tabernero · 2013 · Journal of Clinical Oncology
  36. Targeting DNA repair mechanisms in cancer
    John Michael Furgason, El Mustapha Bahassi · 2012 · Pharmacology & Therapeutics
  37. Chemotherapy and signaling
    Tetyana Bagnyukova, Ilya G. Serebriiskii, Yan Zhou, Elizabeth A. Hopper-Borge, Erica A. Golemis, Igor A. Astsaturov · 2010 · Cancer Biology & Therapy
  38. Chemotherapeutic Compounds Targeting the DNA Double-Strand Break Repair Pathways: The Good, the Bad, and the Promising
    Christian Jekimovs, Emma Bolderson, Amila Suraweera, Mark N. Adams, Kenneth John O'Byrne, Derek J. Richard · 2014 · Frontiers in Oncology
  39. Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP
    Yuan Yuan, Yu-Min Liao, Chung-Tsen Hsueh, Hamid Mirshahidi · 2011 · Journal of Hematology & Oncology
  40. Epigenetics as a Therapeutic Target in Breast Cancer
    Connolly, Roisin, Stearns, Vered · 2012 · Journal of Mammary Gland Biology and Neoplasia
  41. Advances and perspectives of PARP inhibitors
    Yi, Ming, Dong, Bing, Qin, Shuang, Chu, Qian, Wu, Kongming, Luo, Suxia · 2019 · Experimental Hematology & Oncology
  42. Hereditary Breast Cancer: Clinical, Pathological and Molecular Characteristics
    Martin Jakob Larsen, Mads Thomassen, Anne‐Marie Gerdes, Torben Arvid Kruse · 2014 · Breast Cancer Basic and Clinical Research
  43. Structural Basis for the Interaction between Tankyrase-2 and a Potent Wnt-Signaling Inhibitor
    T. Karlberg, Natalia Markova, Ida Johansson, Martin Hammarström, P. Schutz, Johan Weigelt, Herwig Schuler · 2010 · Journal of Medicinal Chemistry
  44. PARP-1: Friend or Foe of DNA Damage and Repair in Tumorigenesis?
    Amanda F. Swindall, Jennifer Anne Stanley, Eddy Shih-Hsin Yang · 2013 · Cancers
  45. PARP Inhibition Sensitizes to Low Dose-Rate Radiation TMPRSS2-ERG Fusion Gene-Expressing and PTEN-Deficient Prostate Cancer Cells
    Payel Chatterjee, Gaurav S. Choudhary, Arishya Sharma, Kamini Singh, Warren D.W. Heston, Jay P. Ciezki, Eric A. Klein, Alexandru Almasan · 2013 · PLoS ONE
  46. Molecular Biological Aspects on Canine and Human Mammary Tumors
    Patricio Rivera, Henrik von Euler · 2010 · Veterinary Pathology
  47. Development of synthetic lethality in cancer: molecular and cellular classification
    Shijie Li, Win Topatana, Sarun Juengpanich, Jiasheng Cao, Jiahao Hu, Bin Zhang, Diana Ma, Xiujun Cai, Mingyu Chen · 2020 · Signal Transduction and Targeted Therapy
  48. Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations
    Sabine Schmid, Aurelius Gabriel Omlin, Celestia S. Higano, Christopher J. Sweeney, Nieves Martínez Chanzá, Niven Mehra, Malou C. P. Kuppen, Himisha Beltran, Vincenza Conteduca, Daniel Vargas Pivato de Almeida et al. · 2020 · JAMA Network Open
  49. Classifications within Molecular Subtypes Enables Identification of BRCA1/BRCA2 Mutation Carriers by RNA Tumor Profiling
    Martin Jakob Larsen, Torben Arvid Kruse, Qihua Tan, Anne‐Vibeke Lænkholm, Martin Bak, Anne E. Lykkesfeldt, Kristina Pilekær Sørensen, Thomas van Overeem Hansen, Bent Ejlertsen, Anne‐Marie Gerdes et al. · 2013 · PLoS ONE
  50. Links between genome integrity and BRCA1 tumor suppression
    Mischa Li Covington, Roger A. Greenberg · 2012 · Trends in Biochemical Sciences
  51. Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors
    Patricia Mucci LoRusso, Jing Li, Angelika M. Burger, Lance K. Heilbrun, Edward A. Sausville, Scott Anthony Boerner, Daryn W. Smith, Mary Jo Pilat, Jie Zhang, Sara M. Tolaney et al. · 2016 · Clinical Cancer Research
  52. Benchmarking of Mutation Diagnostics in Clinical Lung Cancer Specimens
    Silvia Querings, Janine Altmüller, Sascha Ansén, Thomas Zander, Danila Seidel, Franziska Gabler, Martin Peifer, Eva Markert, KATHRYN C. STEMSHORN, Bernd Timmermann et al. · 2011 · PLoS ONE
  53. The tandem duplicator phenotype as a distinct genomic configuration in cancer
    Francesca Menghi, Koichiro Inaki, Xingyi Woo, Pooja Kumar, Krzysztof R. Grzȩda, Ankit Malhotra, Vinod Kumar Yadav, Hyunsoo Kim, Eladio J. Márquez, Duygu Ucar et al. · 2016 · Proceedings of the National Academy of Sciences
  54. Inhibition of PI3K-AKT-mTOR pathway sensitizes endometrial cancer cell lines to PARP inhibitors
    Charles‐André Philip, Ido Laskov, M.-C. Beauchamp, Maud Marques, Oreekha Amin, Joanna Bitharas, Roy Kessous, Liron Kogan, Tahira Baloch, Walter Henri Gotlieb et al. · 2017 · BMC Cancer
  55. Racial disparities in prostate cancer: A complex interplay between socioeconomic inequities and genomics
    Dallin Lowder, Kinza Rizwan, Collin McColl, Alyssa T. Paparella, Michael Ittmann, Nicholas Mitsiades, Salma Kaochar · 2022 · Cancer Letters
  56. Salivary duct carcinomas can be classified into luminal androgen receptor‐positive, HER2 and basal‐like phenotypes*
    Silvana Di Palma, Roderick H.W. Simpson, Caterina Marchiò, Alena Skálová, Marco Ungari, Ann Sandison, Stephen J. Whitaker, Suzanne Parry, Jorge Sergio Reis-Filho · 2012 · Histopathology
  57. Survival in epithelial ovarian cancer: a multivariate analysis incorporating BRCA mutation status and platinum sensitivity
    David James Gallagher, Jason A. Konner, K.M. Bell-McGuinn, Jasmine Bhatia, Paul J. Sabbatini, Carol A Aghajanian, Kenneth Offit, R.R. Barakat, David R. Spriggs, Noah D. Kauff · 2010 · Annals of Oncology
  58. Suberoylanilide hydroxamic acid (SAHA) enhances olaparib activity by targeting homologous recombination DNA repair in ovarian cancer
    Panagiotis A. Konstantinopoulos, Andrew J. Wilson, Jeanette L. Saskowski, Erica Wass, Dineo Khabele · 2014 · Gynecologic Oncology
  59. Biomarkers in Pancreatic Cancer
    Zhi Ven Fong, Jordan Michael Winter · 2012 · The Cancer Journal
  60. Synthetic Lethal Interactions between EGFR and PARP Inhibition in Human Triple Negative Breast Cancer Cells
    Somaira Nowsheen, Tiffiny S. Cooper, Jennifer Anne Stanley, Eddy Shih-Hsin Yang · 2012 · PLoS ONE
  61. Inherited DNA-Repair Defects in Colorectal Cancer
    Saud H. AlDubayan, Marios Giannakis, Nathanael D. Moore, G. Celine Han, Brendan Michael Reardon, Tsuyoshi Hamada, Xinmeng Jasmine Mu, Reiko Nishihara, Zhirong Qian, Li Liu et al. · 2018 · The American Journal of Human Genetics
  62. Chromodomain Helicase DNA-binding Protein 4 (CHD4) Regulates Homologous Recombination DNA Repair, and Its Deficiency Sensitizes Cells to Poly(ADP-ribose) Polymerase (PARP) Inhibitor Treatment
    Mei‐Ren Pan, Hui-Ju Hsieh, Hui Dai, Wen-Chun Hung, Kaiyi Li, Guang Peng, Shiaw‐Yih Lin · 2012 · Journal of Biological Chemistry
  63. BRCA1-deficient mammary tumor cells are dependent on EZH2 expression and sensitive to Polycomb Repressive Complex 2-inhibitor 3-deazaneplanocin A
    Julian Puppe, Rinske Drost, Xiaoling Liu, Simon Andreas Joosse, Bastiaan Evers, Paulien Cornelissen‐Steijger, Petra M. Nederlof, Qiang Yu, Jos Jonkers, Maarten van Lohuizen et al. · 2009 · Breast Cancer Research
  64. Use of γH2AX and Other Biomarkers of Double-Strand Breaks During Radiotherapy
    Ali Sak, Martin Stuschke · 2010 · Seminars in Radiation Oncology
  65. Predictive biomarkers for cancer therapy with PARP inhibitors
    Judith Michels, Ilio Vitale, Murat K. Saparbaev, Maria Castedo, Guido Kroemer · 2013 · Oncogene
  66. The potential of exploiting DNA-repair defects for optimizing lung cancer treatment
    Sophie C. Postel-Vinay, Elsa Vanhecke, Ken André Olaussen, Christopher J. Lord, Alan Ashworth, Jean‐Charles Soria · 2012 · Nature Reviews Clinical Oncology
  67. The Landscape of Pancreatic Cancer Therapeutic Resistance Mechanisms
    Saswati N. Chand, Kevin O’Hayer, Fernando F. Blanco, Jordan Michael Winter, Jonathan Robert Brody · 2016 · International Journal of Biological Sciences
  68. Current status and future prospects of PARP inhibitor clinical trials in ovarian cancer
    Xuan Jiang, Weihua Li, Xiaoying Li, Huimin Bai, Zhenyu Zhang · 2019 · Cancer Management and Research
  69. The roles of RNA in DNA double-strand break repair
    Aldo S. Bader, Ben R Hawley, Ania Wilczynska, Martin Bushell · 2020 · British Journal of Cancer
  70. An update on PARP inhibitors for the treatment of cancer
    Marcia Hall, Sarah Benafif · 2015 · OncoTargets and Therapy
  71. Targeting nucleocytoplasmic transport in cancer therapy
    Richard Hill, Bastien Cautain, Nuria de Pedro, Wolfgang Link · 2013 · Oncotarget
  72. PARP Trapping Beyond Homologous Recombination and Platinum Sensitivity in Cancers
    Junko Murai, Yves G. Pommier · 2018 · Annual Review of Cancer Biology
  73. CCT241533 Is a Potent and Selective Inhibitor of CHK2 that Potentiates the Cytotoxicity of PARP Inhibitors
    Victoria E. Anderson, Michael I. Walton, Paul D. Eve, Katherine J. Boxall, Laurent Antoni, John Caldwell, Wynne Aherne, Laurence H. Pearl, Antony W. Oliver, Ian Collins et al. · 2011 · Cancer Research
  74. Doubling Down on the PI3K-AKT-mTOR Pathway Enhances the Antitumor Efficacy of PARP Inhibitor in Triple Negative Breast Cancer Model beyond BRCA-ness
    Pradip K. De, Yuling Sun, Jennifer H. Carlson, Lori S. Friedman, Brian R Leyland-Jones, Nandini Dey · 2014 · Neoplasia
  75. Strategies for modern biomarker and drug development in oncology
    Alan David Smith, Desam Roda, Timothy Anthony Yap · 2014 · Journal of Hematology & Oncology
  76. Therapeutic Potential of the Poly(ADP-ribose) Polymerase Inhibitor Rucaparib for the Treatment of Sporadic Human Ovarian Cancer
    Maike Ihnen, Christine zu Eulenburg, Teodora R. Kolarova, Jing Wei Qi, Kanthinh Manivong, Meenal Chalukya, Judy Dering, Lee A. Anderson, Charles Ginther, Alexandra Meuter et al. · 2013 · Molecular Cancer Therapeutics
  77. Extent of radiosensitization by the PARP inhibitor olaparib depends on its dose, the radiation dose and the integrity of the homologous recombination pathway of tumor cells
    Caroline V.M. Verhagen, Rosemarie de Haan, Floor Hageman, Tim P.D. Oostendorp, Annalisa L. E. Carli, Mark J. O’Connor, Jos Jonkers, Marcel Verheij, Michiel W. M. van den Brekel, Conchita Vens · 2015 · Radiotherapy and Oncology
  78. Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy
    Marieke A. Vollebergh, Esther H. Lips, Petra M. Nederlof, Lodewyk F.A. Wessels, Jelle Wesseling, Marc J. van de Vijver, Elisabeth G.E. de Vries, Harm van Tinteren, Jos Jonkers, Michael Hauptmann et al. · 2014 · Breast Cancer Research
  79. PARP1 Inhibitors: Antitumor Drug Design
    Natalia V. Maluchenko, E. Yu. Kotova, Olga I. Kulaeva, Mikhail P. Kirpichnikov, V. M. Studitskiy · 2015 · Acta Naturae
  80. The translational challenges of precision oncology
    Oriol Pich, Chris Bailey, Thomas B.K. Watkins, Simone Zaccaria, Mariam Jamal‐Hanjani, Charles Swanton · 2022 · Cancer Cell
  81. DNA Double Strand Break Repair: A Radiation Perspective
    Joy N. Kavanagh, Kelly M. Redmond, Giuseppe Schettino, Kevin M. Prise · 2013 · Antioxidants and Redox Signaling
  82. Health disparities in breast cancer: biology meets socioeconomic status
    Barbara Karen Dunn, Tanya Agurs‐Collins, Doris Browne, Ronald A. Lubet, Karen A. Johnson · 2010 · Breast Cancer Research and Treatment
  83. Validation of the royal marsden hospital prognostic score in patients treated in the phase I clinical trials program at the MD Anderson Cancer Center
    Ignacio Garrido‐Laguna, Filip Jankú, Christos Vaklavas, Gerald Steven Falchook, Siqing Fu, David S. Hong, Aung Naing, Apostolia Maria Tsimberidou, Sijin Wen, Razelle Kurzrock · 2011 · Cancer
  84. Decreased Prostate Cancer-Specific Survival of Men withBRCA2 Mutations from Multiple Breast Cancer Families
    Heather Thorne, Amber J. Willems, Eveline Niedermayr, Ivan Hoh, Jason Li, David R. Clouston, Gillian Mitchell, Stephen B. Fox, John Llewelyn Hopper, Damien Michael Bolton · 2011 · Cancer Prevention Research
  85. Exploiting synthetic lethal interactions for targeted cancer therapy
    Hans Christian Reinhardt, Hai Jiang, Michael T. Hemann, Michael B. Yaffe · 2009 · Cell Cycle
  86. The PARP inhibitor AZD2281 (Olaparib) induces autophagy/mitophagy in BRCA1 and BRCA2 mutant breast cancer cells
    Banu Arun, Uǧur Akar, Angelica M. Gutierrez‐Barrera, Gabriel N. Hortobágyi, Bülent Özpolat · 2015 · International Journal of Oncology
  87. The Elephant and the Blind Men: Making Sense of PARP Inhibitors in Homologous Recombination Deficient Tumor Cells
    Silvana B. De Lorenzo, Anand G. Patel, Rachel M. Hurley, Scott H. Kaufmann · 2013 · Frontiers in Oncology
  88. CpG island hypermethylation of BRCA1 and loss of pRb as co-occurring events in basal/triple-negative breast cancer
    Ólafur Andri Stefánsson, Jon Gunnlaugur Jonasson, Kristrún Ólafsdóttir, Hólmfríður Hilmarsdóttir, Guðríður H. Ólafsdóttir, Manel Esteller, Óskar Þór Jóhannsson, Jorunn Erla Eyfjord · 2011 · Epigenetics
  89. Strategies to design clinical studies to identify predictive biomarkers in cancer research
    José Luis Perez‐Gracia, Miguel F. Sanmamed, Ana Bosch, Ana Patiño‐García, Kurt Alex Schalper, Víctor Segura, Joaquim Bellmunt B, Josep M. Tabernero, Christopher J. Sweeney, Toni K. Choueiri et al. · 2016 · Cancer Treatment Reviews
  90. Imaging Therapeutic PARP Inhibition In Vivo through Bioorthogonally Developed Companion Imaging Agents
    Thomas Reiner, Jessica N. Lacy, Edmund J. Keliher, Katherine S. Yang, Adeeti V. Ullal, Rainer H. Köhler, Claudio Vinegoni, Ralph Weissleder · 2012 · Neoplasia
  91. Massively‐parallel sequencing assists the diagnosis and guided treatment of cancers of unknown primary
    Richard W. Tothill, Jason Li, Linda Mileshkin, Kenneth Doig, Terence Siganakis, Prue A. Cowin, ANDREW P. FELLOWES, Timothy J. Semple, Stephen B. Fox, Keith A. Byron et al. · 2013 · The Journal of Pathology
  92. DNA damage response and prostate cancer: defects, regulation and therapeutic implications
    Styliani Karanika, Theodoros Karantanos, Leping Li, Paul Gettys Corn, Timothy C. Thompson · 2014 · Oncogene
  93. Histone Deacetylase Regulation of ATM-Mediated DNA Damage Signaling
    Kenneth T. Thurn, Scott Thomas, Paromita Raha, Ian Qureshi, Pamela N. Münster · 2013 · Molecular Cancer Therapeutics
  94. BRCA1, PARP, and 53BP1: conditional synthetic lethality and synthetic viability
    A. Aly, Shridar Ganesan · 2011 · Journal of Molecular Cell Biology
  95. RAD51 as a potential surrogate marker for DNA repair capacity in solid malignancies
    Mariam A. Gachechiladze, Jozef Škarda, Alex Soltermann, Markus Joerger · 2017 · International Journal of Cancer
  96. PARP1 in Carcinomas and PARP1 Inhibitors as Antineoplastic Drugs
    Luyao Wang, Chao Liang, Fangfei Li, Daogang Guan, Xiaoqiu Wu, Xuekun Fu, Aiping Lü, Ge Zhang · 2017 · International Journal of Molecular Sciences
  97. The role of PARP inhibition in triple-negative breast cancer: Unraveling the wide spectrum of synthetic lethality
    Marios Papadimitriou, Giannis Mountzios, CHRISTOS A. PAPADIMITRIOU · 2018 · Cancer Treatment Reviews
  98. ATM-Deficient Cancers Provide New Opportunities for Precision Oncology
    Nicholas Jette, Mehul Kumar, Suraj Radhamani, Greydon Arthur, Siddhartha Goutam, Steven Yip, Michael Paul Kolinsky, Gareth J. Williams, Pinaki Bose, Susan P. Lees‐Miller · 2020 · Cancers
  99. Pre-clinical and clinical evaluation of PARP inhibitors as tumour-specific radiosensitisers
    C. Bethan Powell, Christos Mikropoulos, Stan B. Kaye, Chris M. Nutting, S. Bhide, Kate L. Newbold, Kevin Joseph Harrington · 2010 · Cancer Treatment Reviews
  100. CAR-T “the living drugs”, immune checkpoint inhibitors, and precision medicine: a new era of cancer therapy
    Delong Liu · 2019 · Journal of Hematology & Oncology